Kiran Naqvi is an Oncology physician affiliated with University of California, Irvine. OpenAlex indexes 227 publications with 4,386 citations (h-index 34).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
101 The City Dr S
Orange, CA 928683201
Telephone
832-909-5763Provider last certified this registry record 14 Oct 2022.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Geron CorporationProgram year20255 payments
- Syndax Pharmaceuticals, Inc.Program year20253 payments
- BeOne Medicines USA, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
29%Fluoroquinolone Antibacterial16.2%Levofloxacin100%Part D≥15 patientsAzole Antifungal12.8%Posaconazole100%Part D≥12 patientsMetabolism & gastrointestinal
21.1%Proton pump inhibitor10.2%Pantoprazole Sodium72%Rabeprazole Sodium28%Part D<11 patientsPotassium supplement8.1%Potassium Chloride100%Part D<11 patients+ 1 more class in this area
Dermatology
18.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor18.3%Acyclovir100%Part D≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Journal of Clinical Oncology
2022 - A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
American Journal of Hematology
2022 - Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome
British Journal of Haematology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Susan O’Brien, MD
University of California, Irvine
Steven Potkin, MD
University of California, Irvine
Mitchell Brin, MD
University of California, Irvine
Deborah Wing, MD
University of California, Irvine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”